- Home
- JMM vs TIL Comparison
JMM vs TIL Comparison
Compare JMM & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JMM | TIL |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.2M | 48.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | JMM | TIL |
|---|---|---|
| Price | $5.80 | $7.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 6.1K | ★ 9.5K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 5.44% | N/A |
| EPS Growth | N/A | ★ 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.67 | $5.67 |
| 52 Week High | $6.52 | $33.83 |
Technical Indicators
Market Signals| Indicator | JMM | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 48.04 | N/A |
| Support Level | $5.77 | N/A |
| Resistance Level | $5.89 | N/A |
| Average True Range (ATR) | 0.05 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 58.82 | 0.00 |
Price Performance
Historical ComparisonAbout JMM Nuveen Multi-Market Income Fund (MA)
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.